Paris, France – June 11^th, 2024

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, will present data on its innovative OncoMimics^™ approach to cancer therapy at the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), taking place June 10-13 in Rotterdam, Netherlands. The presentation describes Enterome’s OncoMimics^™ peptide-based immunotherapy, designed to harness the patient’s immune system to target and eliminate cancer cells.

Dr. Alice Talpin, lead researcher, commented: “The OncoMimics^™ approach offers a promising strategy to enhance cancer immunity by overcoming the limitations of current vaccines. Our preclinical and clinical data underscore the ability of OncoMimics^™ peptides to elicit strong, durable immune responses, which could significantly improve patient outcomes.”

Peptide-based immunotherapy offers significant potential against cancer by leveraging the body’s immune system to eliminate cancer cells, targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Enterome innovative OncoMimics^™ therapies are based on the concept of molecular mimicry and cross-reactivity between commensal-derived synthetic peptides and tumor-associated antigens-derived peptides (TAAps) to evoke a CD8⁺ T cell response against tumors.

Based on this approach, Enterome has developed a pipeline of drug candidates for the treatment of cancer, including EO2463, which is demonstrating a favorable safety profile with encouraging early signs of efficacy in a Phase 2 clinical trial (EONHL1-20/SIDNEY) for indolent non-Hodgkin lymphomas, and EO2401, which has successfully completed a Phase 2 clinical trial (EOGBM1-18/ROSALIE) in patients with recurrent glioblastoma.

Highlights from the EACR 2024 poster presentation, entitled Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens:

In humanized HLA-A2 murine models, OncoMimics^™ peptides (OMPs) trigger the expansion of cross-reactive OMP-/TAAp- specific CD8⁺ T cells with specific cytotoxic activity against tumor cells. Experiments conducted on HLA-A2⁺ healthy human peripheral blood mononuclear cells revealed a high prevalence of cross-reactive OMP-/TAAp-specific CD8⁺ T cells when stimulated in vitro. In addition, those cross-reactive CD8⁺ T cells exhibit cytolytic activity against target cells presenting homologous TAAs.

Abstract #1155 is published in an online supplement to Molecular Oncology (Volume 18, Issue S1, DOI: 10.1002/1878-0261.13683) and the Poster will be available on Enterome’s website following the session.

Poster #1155 Presentation details

 Title: Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens

Presenting Author: Alice Talpin, PhD, Enterome researcher

Poster Session: Immunotherapy (odd Abstract Numbers)

Poster Board: P-285

Session Date and Time: June 12, 18:40 to 20:15 CET (poster displayed from 11:00 CET)

Download the press release (.pdf format)